Advertisement

Topics

Aravive Biologics Initiates Phase 1 Study of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500

08:00 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred...

Other Sources for this Article

Aravive Biologics, Inc.
Danielle Malloy
Director, Corporate Operations
Info@aravive.com
or
Joan E. Kureczka, 415-821-2413
Joan@bioscribe.com

NEXT ARTICLE

More From BioPortfolio on "Aravive Biologics Initiates Phase 1 Study of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...